Mutaflor: A New Treatment Option for Ulcerative Colitis now available to
Canadians

RICHMOND HILL, ON, June 14 /CNW/ - Medical Futures Inc. is pleased to announce Mutaflor, a probiotic treatment for preventing and/or maintaining remission of ulcerative colitis and for chronic constipation.

Paul Johns, VP Sales and Marketing for MFI, says: "We have a strong belief in probiotics providing significant health benefits, especially probiotics with the pedigree and strong scientific support that Mutaflor brings." MFI has a successful track record in the probiotic arena and actively seeks out products in this area. "We are expecting Mutaflor to be accepted into practice quickly in North America because of its established health benefits and also because the complexity of the condition, ulcerative colitis, and the limited efficacy of standard treatments leaves significant room for new products."

About the product

Mutaflor is a probiotic that has been shown to help healing in ulcerative colitis. It is safe for long term use as these patients may require treatment for many years. Efficacy has been established in several blinded, randomized, controlled trials against the current standard of care, 5-ASAs. Mutaflor has been researched and used clinically for over 90 years in other parts of the world. Canadians can purchase Mutaflor online now at www.Mutaflor.ca.

About Medical Futures

Medical Futures Inc. Richmond Hill, Canada, is a niche pharmaceutical company that distributes both pharmaceutical and natural therapeutic products into the North American marketplace. Founded in 2000, this privately held company is dedicated to advancing the quality of life for all North Americans.

For further information: about Medical Futures, go to www.medfutures.com